&!2D}/J65|$1LRG#B<KB}T-<581^G19F0@
SYSTEM PROCESSING...
&!2D}/J65|$1LRG#B<KB}T-<581^G19F0@
SYSTEM PROCESSING...
Posted: 2025-05-31 22:01:28 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-05-31 22:02:52 UTC
Verified By
Rollup News
Moderna's new COVID-19 vaccine, mNEXSPIKE, has been approved by the FDA for individuals aged 65 and older, as well as those with risk factors. It offers improved performance compared to Spikevax and does not require freezing. Moderna hopes this new vaccine will boost sales, while pandemic strategies are being adjusted with less enthusiasm.
FDA approval of Moderna's mNEXSPIKE vaccine
Targeted use for 65+ and high-risk individuals
Improved convenience with no freezer requirement
Moderna's hope for sales revival
Slumping sales of previous vaccines
Reduced enthusiasm for pandemic measures
Limited initial target demographic